ARS Pharmaceuticals, Inc. officer Eric Karas filed a Form 144 notice of proposed sale on November 9, 2026, disclosing plans to sell 139,588 shares of common stock acquired through a stock option exercise on the same date.

Key Highlights

  • Proposed sale: Eric Karas, an officer of ARS Pharmaceuticals, Inc., intends to sell 139,588 shares of common stock with an aggregate market value of $402,362.41.
  • Acquisition method: The 139,588 shares were acquired on November 9, 2026, via a stock option exercise from the issuer, with cash payment on the same date.
  • Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Exchange and shares outstanding: The securities are listed on NASDAQ, and the filing states 100,528,400 shares of common stock outstanding.
  • Prior sales in past 3 months: According to the filing, Karas sold a combined 394,064 shares in four separate transactions between September 11, 2026, and October 30, 2026, generating gross proceeds totaling $1,607,930.43.

Eric Karas Proposes Additional Common Stock Sale at ARS Pharmaceuticals

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 9, 2026, Eric Karas, identified in the filing as an officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), disclosed a proposed sale of 139,588 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $402,362.41, and the approximate date of sale is stated as November 9, 2026.

The filing indicates that the shares were acquired on November 9, 2026, through a stock option exercise from the issuer, with cash paid as consideration on the same date. No portion of the purchase price was indicated as deferred or paid through non-cash means.

The filing also discloses Karas's sales of ARS Pharmaceuticals common stock during the three months preceding the notice. Those prior sales, as reported, include: 14,064 shares on September 11, 2026, with gross proceeds of $69,761.66; 100,000 shares on September 30, 2026, with gross proceeds of $431,560.00; 100,000 shares on October 1, 2026, with gross proceeds of $426,096.77; 100,000 shares on October 19, 2026, with gross proceeds of $410,240.00; and 80,000 shares on October 30, 2026, with gross proceeds of $270,272.00. ARS Pharmaceuticals, Inc. is headquartered at 11682 El Camino Real, Suite 300, San Diego, California 92130.

What Was Disclosed

ARS Pharmaceuticals officer Eric Karas filed a Form 144 on November 9, 2026, proposing to sell 139,588 shares of common stock with an aggregate market value of $402,362.41, acquired that same day through a stock option exercise, through Morgan Stanley Smith Barney LLC.